Palladium Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $43.4M | Sell |
151,670
-391
| -0.3% | -$101K | 1.91% | 9 |
|
|
2021
Q4 | $42M | Sell |
152,061
-611
| -0.4% | -$155K | 1.72% | 11 |
|
|
2021
Q3 | $35.3M | Sell |
152,672
-640
| -0.4% | -$158K | 1.61% | 13 |
|
|
2021
Q2 | $35.2M | Sell |
153,312
-417
| -0.3% | -$83.8K | 1.66% | 13 |
|
|
2021
Q1 | $28.7M | Sell |
153,729
-602
| -0.4% | -$118K | 1.43% | 17 |
|
|
2020
Q4 | $26.1M | Sell |
154,331
-1,770
| -1% | -$264K | 1.44% | 18 |
|
|
2020
Q3 | $23.1M | Sell |
156,101
-1,531
| -1% | -$237K | 1.46% | 19 |
|
|
2020
Q2 | $25.9M | Sell |
157,632
-899
| -0.6% | -$138K | 1.77% | 14 |
|
|
2020
Q1 | $22M | Sell |
158,531
-667
| -0.4% | -$91.6K | 1.83% | 13 |
|
|
2019
Q4 | $20.9M | Sell |
159,198
-72,198
| -31% | -$8.37M | 1.34% | 19 |
|
|
2019
Q3 | $24.8M | Buy |
231,396
+70,088
| +43% | +$7.8M | 1.73% | 13 |
|
|
2019
Q2 | $17.9M | Sell |
161,308
-1,895
| -1% | -$223K | 1.24% | 22 |
|
|
2019
Q1 | $21.2M | Sell |
163,203
-66,530
| -29% | -$8.09M | 1.53% | 17 |
|
|
2018
Q4 | $26.6M | Sell |
229,733
-4,185
| -2% | -$467K | 2.12% | 9 |
|
|
2018
Q3 | $25.1M | Buy |
233,918
+3,380
| +1% | +$338K | 1.71% | 13 |
|
|
2018
Q2 | $19.7M | Buy |
230,538
+8,130
| +4% | +$668K | 1.43% | 16 |
|
|
2018
Q1 | $17.2M | Buy |
222,408
+7,815
| +4% | +$629K | 1.27% | 22 |
|
|
2017
Q4 | $18.1M | Buy |
214,593
+7,290
| +4% | +$620K | 1.31% | 20 |
|
|
2017
Q3 | $17.7M | Buy |
207,303
+61,350
| +42% | +$5.03M | 1.35% | 21 |
|
|
2017
Q2 | $12M | Sell |
145,953
-1,425
| -1% | -$116K | 0.95% | 33 |
|
|
2017
Q1 | $12.4M | Sell |
147,378
-1,185
| -0.8% | -$94.9K | 1% | 29 |
|
|
2016
Q4 | $10.9M | Sell |
148,563
-3,828
| -3% | -$285K | 0.92% | 32 |
|
|
2016
Q3 | $12.2M | Buy |
152,391
+1,640
| +1% | +$131K | 1.07% | 24 |
|
|
2016
Q2 | $11.9M | Buy |
150,751
+362
| +0.2% | +$27.3K | 1.08% | 26 |
|
|
2016
Q1 | $10.8M | Sell |
150,389
-1,825
| -1% | -$138K | 0.99% | 32 |
|
|
2015
Q4 | $12.8M | Buy |
152,214
+531
| +0.4% | +$44.1K | 1.19% | 26 |
|
|
2015
Q3 | $12.7M | Sell |
151,683
-375
| -0.2% | -$31.7K | 1.25% | 26 |
|
|
2015
Q2 | $12.7M | Sell |
152,058
-200
| -0.1% | -$15.2K | 1.13% | 27 |
|
|
2015
Q1 | $11.1M | Hold |
152,258
| – | – | 0.95% | 32 |
|
|
2014
Q4 | $10.5M | Sell |
152,258
-225
| -0.1% | -$15.2K | 0.91% | 30 |
|
|
2014
Q3 | $9.89M | Sell |
152,483
-1,739
| -1% | -$110K | 0.89% | 36 |
|
|
2014
Q2 | $9.59M | Sell |
154,222
-86,000
| -36% | -$5.13M | 0.85% | 37 |
|
|
2014
Q1 | $14.1M | Sell |
240,222
-7,060
| -3% | -$394K | 1.29% | 22 |
|
|
2013
Q4 | $12.6M | Sell |
247,282
-6,910
| -3% | -$346K | 1.2% | 24 |
|
|
2013
Q3 | $12.8M | Buy |
254,192
+575
| +0.2% | +$30.1K | 1.3% | 20 |
|
|
2013
Q2 | $12.5M | Buy |
+253,617
| New | +$13.8M | 1.31% | 17 |
|
Other funds holding LLY
Palladium Partners's LLY Position: Q1 2022 in Review
Palladium Partners reduced its Eli Lilly (LLY) stake by 0.26% in Q1 2022, selling an estimated $101K and leaving 151,670 shares worth $43.4M. The position accounts for 1.91% of the portfolio, ranked #9.
Palladium Partners first reported a position in LLY in Q2 2013 and has held it in 36 quarters since. 2,346 funds tracked by Wall St. Rank hold LLY as of Q1 2022.
- Palladium Partners held 151,670 shares of Eli Lilly worth $43.4M as of Q1 2022.
- Palladium Partners sold 391 Eli Lilly shares in Q1 2022, an estimated $101K.
- Eli Lilly made up 1.91% of Palladium Partners's portfolio in Q1 2022, its #9 holding.
- Palladium Partners first reported a position in Eli Lilly in Q2 2013 and has held it in 36 quarters since.
- 2,346 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2022.
Based on Palladium Partners's 13F filing for Q1 2022, filed 26 Apr 2022.